Beyond PD-L1: Refining First-Line Treatment Decisions in Metastatic NSCLC

Podcast: OncLive® On Air · OncLive® On Air

Opublikowano: 2026-10-21

In this episode of OncLive On Air, Aditya Juloori, MD, a radiation oncologist and associate professor at the University of Chicago in Illinois, was joined by David Carbone, MD, PhD, a thoracic medical oncologist and director of the Thoracic Oncology Center at The Ohio State University in Columbus. Together, they explored how factors beyond PD-L1 expression, including histology, co-occurring genomic alterations, brain metastases, and patient fitness, can inform first-line regimen selection for patients with driver-negative metastatic non–small cell lung cancer (NSCLC). Dr Carbone began by explaining that immunotherapy has transformed the treatment landscape, with frontline regimens no...